AKYNZEO® for Injection

Discover the clinical data supporting AKYNZEO for Injection:

The efficacy of AKYNZEO for Injection for the prevention of CINV was established by demonstrating:

Safety of AKYNZEO for Injection was established based on:


Palonosetron administered as an IV infusion was shown to be noninferior to a bolus IV push1

  • Multicenter, multinational, randomized, double-blind study
  • 425 adult cancer patients receiving a non-AC HEC regimen received palonosetron (PALO) plus dexamethasone (DEX) to prevent CINV
    • Bolus IV push arm: Single dose of PALO 0.25 mg administered IV over 30 seconds + DEX
    • IV infusion arm: Single dose of PALO 0.25 mg administered IV over 30 minutes + DEX
  • Primary endpoint: Noninferiority of palonosetron IV infusion to bolus IV push
    • Complete response (CR): No emesis or rescue medication use during the acute phase (0-24 hours after chemotherapy)
    • Prespecified noninferiority margin was set at -15%

CR (no emesis and no use of antiemetic rescue medication) in acute phase (0-24 hours) in non-AC HEC-treated patients1
CR Complete Responce; Dexamethasone, Palonosetron, Oral

  • Patients achieving CR in the acute phase for IV infusion and IV bolus push were 82.7% and 86.3%, respectively
    • Difference of -3.4%; 99% CI -12.0% to 5.2%
  • The frequency and severity of all reported TEAEs were similar between treatment arms

Fosnetupitant in AKYNZEO for Injection demonstrated bioequivalence to netupitant in AKYNZEO Capsules1,2

  • AKYNZEO for Injection is the only combination agent that includes a 5-HT3 receptor antagonist (palonosetron) with an NK-1 RA (netupitant)
  • Netupitant, the NK-1 RA in AKYNZEO Capsules, is not water soluble, so AKYNZEO for Injection includes the soluble prodrug, fosnetupitant
  • Fosnetupitant is rapidly converted to netupitant after IV administration
Plasma concentrations after single dose of fosnetupitant2
Plasma Concentration

Fosnetupitant plasma concentrations decreased rapidly, while netupitant plasma concentrations remained steady over time2


  • The pharmacologic effects of fosnetupitant can be attributed to the activity of netupitant
  • An IV fosnetupitant dose of 235 mg (260 mg of fosnetupitant chloride hydrochloride) achieved a similar netupitant AUC as 300 mg oral netupitant
Linear relationship between fosnetupitant dose and netupitant area under the curve (AUC)2
Linear Relationship between Fosnetupitant dose and Netupitant AUC

The safety profile of AKYNZEO for Injection was generally similar to AKYNZEO Capsules1,3

  • Phase III, multinational, randomized, double-blind, multicycle safety study3
  • 404 patients receiving a cisplatin-based HEC regimen for solid tumors received either oral or IV AKYNZEO to prevent CINV1,3
  • Median age: 60 years; 46% women; 99.5% white; 0.3% Asian; 0.3% Hispanic1
    • Oral arm: Single dose of AKYNZEO Capsule + DEX (n=201)
    • IV arm: Single IV dose of AKYNZEO + DEX (n=203)
    • DEX dose was PO 12 mg on Day 1, followed by 8 mg on Days 2-4 for both arms
  • Safety profile was generally similar between oral and IV formulations1,3
    • TRAEs were observed in 8.9% and 9.5% of patients in IV and PO arms, respectively
    • Severe TRAEs were observed in 0.5% and 1.0% of patients in IV and PO arms, respectively
  • There were no infusion-site reactions related to AKYNZEO for Injection3

AKYNZEO for Injection

In Clinical Trials

  • No anaphylaxis attributed to fosnetupitant (NK-1 RA) reported1,3
  • No significant effect on QTc interval1
  • No infusion-site reactions reported3
  • Contains NO polysorbate 80 (a solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions)1,4

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.
  • AC=anthracycline-cyclophosphamide; AUC=area under the curve; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy; IV=injection for intravenous use; NK-1 RA=NK-1 receptor antagonist; PO=oral; QTc=corrected QT interval; TRAE=treatment-related adverse event.
  • *AKYNZEO for Injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.